Press Releases Year None20222021202020192018201720162015201420132012201120102009 09/10/22 Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 09/07/22 Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 09/06/22 Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September 08/09/22 Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update 07/26/22 Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 07/11/22 Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer 07/07/22 Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies 07/05/22 Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference 06/21/22 Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer 06/16/22 Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies 05/31/22 Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June 05/26/22 Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 05/26/22 Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 05/10/22 Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update 05/04/22 Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May 05/03/22 Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer 04/26/22 Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022 04/14/22 Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma 04/13/22 Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors 03/25/22 Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer 03/14/22 Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer 03/02/22 Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March 02/17/22 Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 02/14/22 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 02/03/22 Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022 02/02/22 Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022 01/18/22 Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 01/09/22 Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 01/06/22 Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor 01/05/22 Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma 01/04/22 Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 01/04/22 Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
